Scholarlink

<p> The European Medicines Agency has recommended testing for the <i>ApoE</i>-genotype prior to treatment of Alzheimer’s disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the <i>ApoE epsilon 4</i> allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetisch informierte Therapie in der Psychiatrie: neue Dynamik durch APOE und Antikörpertherapie der Alzheimer-Krankheit

  • 期刊论文

  • 发表日期：

    2025年6月23日

查看全文
  • Daniel J. Müller,
  • Christine M. Freitag,
  • Urs Heilbronner,
  • Markus M. Nöthen,
  • Robert Perneczky,
  • Marcella Rietschel,
  • Eva C. Schulte,
  • Jürgen Deckert

摘要

The European Medicines Agency has recommended testing for the ApoE-genotype prior to treatment of Alzheimer’s disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the ApoE epsilon 4 allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.